Medicine and Dentistry
Hepatocellular Carcinoma
93%
Neoplasm
82%
Malignant Neoplasm
62%
Overall Survival
48%
Disease
47%
Multiple Myeloma
43%
Magnetic Resonance Imaging
36%
Prostate Cancer
32%
Transitional Cell Carcinoma
28%
Clinical Trial
28%
Myelofibrosis
27%
Liver Transplantation
26%
Chemotherapy
25%
Recurrent Disease
23%
Immunotherapy
23%
Surgery
23%
Diseases
23%
Biological Marker
21%
COVID-19
19%
Cystectomy
19%
Bladder Cancer
19%
Progression Free Survival
18%
Cancer
18%
Myeloproliferative Neoplasm
18%
Hazard Ratio
15%
Immune Checkpoint Inhibitor
15%
Adverse Event
15%
Urothelial Cancer
13%
Metastatic Carcinoma
13%
Lung Cancer
13%
Transplantation
13%
Oncology
13%
Immunity
13%
Cholangiocarcinoma
13%
Cisplatin
13%
Radiation Therapy
12%
Polycythemia vera
12%
Hematopoietic Cell
12%
Arm
12%
Liver Cirrhosis
12%
Systematic Review
12%
Quality of Life
11%
Myelodysplastic Syndrome
11%
Hepatectomy
11%
Muscle Invasive Bladder Cancer
11%
Breast Cancer
10%
Wart Virus
10%
Meta-Analysis
10%
Infection
10%
Biopsy Technique
10%
Ruxolitinib
10%
Acute Myeloid Leukemia
10%
Systemic Therapy
10%
Liver Cancer
10%
Liver Graft
9%
Prostatectomy
9%
Diagnosis
9%
Diffusion MRI
9%
Squamous Cell Carcinoma
9%
T Cell
9%
Oropharynx Carcinoma
9%
Lenalidomide
9%
Chemoradiotherapy
9%
Neck
9%
Survival Rate
8%
Cancer Cell
8%
Head and Neck Cancer
8%
Nivolumab
8%
Myeloma
8%
Neoadjuvant Chemotherapy
8%
Prognostic Factor
7%
Anemia
7%
Placebo
7%
Bladder
7%
Melanoma
7%
Ovarian Cancer
7%
Lymph Node
7%
Radiation Therapy
7%
Cancer Therapy
7%
Targeted Therapy
7%
Sorafenib
7%
In Vitro
6%
Proportional Hazards Model
6%
Combination Therapy
6%
Pelvis
6%
Hepatitis C
6%
Surgery
6%
Living Donors
6%
Non Small Cell Lung Cancer
6%
Clear Cell Renal Cell Carcinoma
6%
Essential Thrombocythaemia
6%
Magnetic Resonance Elastography
6%
Health Care Cost
6%
Neoadjuvant Therapy
6%
Fibrosis
6%
Recurrence Free Survival
6%
Disease Exacerbation
6%
Cohort Analysis
6%
Clinician
6%
Gene Expression
6%
Keyphrases
Hepatocellular Carcinoma
100%
Overall Survival
48%
Tumor
46%
Multiple Myeloma
40%
Myelofibrosis
36%
Confidence Interval
27%
Prostate Cancer
26%
Relapsed or Refractory multiple Myeloma
26%
Myeloproliferative Neoplasms
26%
Clinical Trials
24%
Liver Transplantation
22%
Phase II Trial
22%
Chemotherapy
21%
Liver
20%
Bladder Cancer
20%
Hazard Ratio
19%
High Risk
19%
COVID-19
18%
Immune Checkpoint Inhibitors
18%
Polycythemia Vera
18%
Progression-free Survival
17%
Phase II Study
17%
Resection
16%
Graft-versus-host Disease (GvHD)
16%
United States
15%
Ruxolitinib
15%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
15%
In Cancer
15%
Hematopoietic Stem Cells
14%
Lenalidomide
13%
Acute Myeloid Leukemia
13%
Magnetic Resonance Imaging
13%
Advanced Hepatocellular Carcinoma
12%
Cisplatin
12%
Programmed Death-ligand 1 (PD-L1)
12%
Sorafenib
12%
High-risk Human Papillomavirus (HR-HPV)
12%
Clinical Outcomes
12%
Head-and-neck Cancer
12%
Meta-analysis
12%
Myelodysplastic Syndrome
11%
Muscle-invasive Bladder Cancer
11%
Transplantation
11%
Adverse Events
11%
Bortezomib
11%
Cancer Patients
11%
Mount Sinai
11%
Oropharyngeal Squamous Cell Carcinoma (OPSCC)
10%
Radiation Therapy
10%
Cirrhosis
10%
T Cells
10%
Targeted Therapy
10%
Systemic Therapy
10%
Malignancy
9%
Proteogenomics
9%
Disease Progression
9%
Radical Cystectomy
9%
Upper Tract Urothelial Carcinoma
9%
Gene Signature
9%
Proteolysis Targeting chimera (PROTAC)
9%
Metastatic Urothelial Carcinoma
9%
Lung Cancer
9%
Metastatic Urothelial Cancer
9%
Cancer Cells
9%
Tumor Microenvironment
9%
Placebo
9%
Head-and-neck
9%
Dendritic Cells
9%
Multiparametric MRI (mpMRI)
9%
Myeloma
8%
Bone Marrow
8%
Intrahepatic Cholangiocarcinoma (iCCA)
8%
Risk Factors
8%
Degrader
8%
Anemia
8%
Non-small Cell Lung Cancer (NSCLC)
8%
Monotherapy
8%
Radiotherapy
8%
Nivolumab
8%
Therapeutic Potential
8%
Complete Response
8%
Gene Expression
8%
Essential Thrombocythemia
8%
Thrombocytopenia
8%
Head-and-neck Squamous Cell Carcinoma (HNSCC)
8%
Treatment Options
8%
Median Overall Survival
7%
Systematic Meta-analysis
7%
Alpha-fetoprotein
7%
Overall Response Rate
7%
Neoadjuvant Chemotherapy
7%
Leukemia
7%
Tumor Cells
7%
Response Rate
7%
Enhancer of Zeste Homolog 2 (EZH2)
7%
Small Molecules
7%
Multiple Myeloma Patients
7%
Quality of Life
7%
Prognostic Factors
7%
Combination Therapy
7%